New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 23, 2012
13:15 EDTRIMM, WMT, BAX, ALU, MAPP, OCZOn The Fly: Closing Wrap
Stocks on Wall Street were higher during the post-holiday short session, with each of the major averages adding over 1%. Following an initial move higher in the first hour after the bell, aided by some encouraging economic data from abroad, the indices drifted higher for the remainder of the day and closed at their highs... ECONOMIC EVENTS: In the U.S., no major economic data was released, however, in Europe, separate reports showed business confidence increased in November in both Germany and France. Also, in China, HSBC's Manufacturing Purchasing Managers' Index increased to 50.4, indicating expansion... COMPANY NEWS: Wal-Mart (WMT) announced had its "best ever Black Friday events" in spite of some scattered strikes by workers and shares advanced $1.31, or 1.90%, to $70.20... Research in Motion (RIMM) shares benefited a day after National Bank raised it price target on the stock to $15 from $12. The firm said in a note to investors yesterday that RIM's new management team is executing by maintaining the BlackBerry subscriber base and U.S. listed shares rose $1.40, or 13.65%, to $11.66 in their first day of trading following the bullish write-up... Shares of Baxter (BAX) moved up $2.69, or 4.07%, to $68.81 after The Wall Street Journal said the company is in talks to buy medical-equipment maker Gambro for about $4B to round out its kidney-dialysis business... MAJOR MOVERS: Among the notable gainers were Alcatel-Lucent (ALU), up 10c, or 10.00%, to $1.10 after Bloomberg said the company is in talks with Goldman Sachs (GS) on a loan to strengthen its balance sheet, and MAP Pharmaceuticals (MAPP), up $2.60, or 20.28%, to $15.42 after the company announced that the FDA accepted its Levadex resubmission with a six-month review. Among the noteworthy losers was OCZ Technology (OCZ), which fell 3c, or 2.52%, to $1.16 following its disclosure of a SEC inquiry... INDICES: The Dow was up 172.79, or 1.35%, to 13,009.68; the Nasdaq was up 40.30, or 1.38%, to 2,966.85; and the S&P 500 was up 18.12, or 1.30%, to 1,409.15.
News For RIMM;WMT;BAX;ALU;MAPP;OCZ From The Last 14 Days
Check below for free stories on RIMM;WMT;BAX;ALU;MAPP;OCZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
13:23 EDTBAXGoldman to hold a conference
Subscribe for More Information
August 29, 2014
08:07 EDTWMTWal-Mart challenges Alibaba with additions to online site in China, WSJ says
Subscribe for More Information
August 28, 2014
09:57 EDTALUOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:29 EDTALUAlcatel-Lucent removed from Europe 1 List at BofA/Merrill
Subscribe for More Information
06:51 EDTALUAlcatel-Lucent upgraded to Outperform from Market Perform at Bernstein
August 27, 2014
09:08 EDTBAXNektar could see $100M in revenue from Baxter drug, says Roth Capital
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
August 25, 2014
13:47 EDTWMTWal-Mart launching chip-enabled store-brand MasterCard
Subscribe for More Information
August 24, 2014
21:53 EDTWMTNational Association of Chain Drug Stores to hold an expo
2014 NACDS Total Store Expo to be held in Boston on August 23-25.
August 21, 2014
15:37 EDTBAXNektar: Baxter announces positive results from Phase 3 study of BAX 855
Nektar Therapeutics (NKTR) reports Baxter International (BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 - 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study
13:23 EDTWMTWal-Mart cut iPhone prices, Washington Post says
Wal-Mart (WMT) today began selling Apple's (AAPL) iPhone 5s for $79, and cut the price of the iPhone 5c to just 97c, according to The Washington Post. The devices previously cost $99 and $29 respectively at Wal-Mart, the newspaper stated. Reference Link
10:34 EDTWMTOptions Update; August 21, 2014
Subscribe for More Information
09:37 EDTWMTActive equity options trading on open
Subscribe for More Information
09:02 EDTBAXBaxter announces BAX 855 met primary endpoint in Phase 3 study
Baxter announced "positive" results from its Phase 3 pivotal clinical trial of BAX 855, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median ABR as compared to those in the on-demand arm. BAX 855 was also effective in treating bleeding episodes, 96% of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study.
August 20, 2014
12:38 EDTALUAlcatel-Lucent announces early repayment of $1.75B credit facility
Alcatel-Lucent announced today that its affiliate Alcatel-Lucent USA has repaid early and in full the senior secured credit facility of an initial principal amount of 1.75B entered into on January 30, 2013. The senior secured credit facility was secured by various first-priority pledges on a material portion of the Alcatel-Lucent Group's assets. The pledges will be consequently cancelled and released.
08:30 EDTWMTWal-Mart management to meet with MKM Partners
Subscribe for More Information
August 19, 2014
16:33 EDTBAXBaxter to expand Alabama facility to increase dialyzers production
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use